NCT07050472View on ClinicalTrials.gov

Durvalumab After Concurrent Chemoradiotherapy (cCRT) for Limited-stage Small-cell Lung Cancer (LS-SCLC)

Not yet recruitingOBSERVATIONAL

Enrollment

40

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions

Small-cell Lung Cancer

Trial Locations (1)

100142

Peking University Cancer Hospital and Institute, Beijing

All Listed Sponsors

lead

Anhui Shi, MD

OTHER